Advances in management and treatment of tubercular meningitis - a narrative review.

IF 1.6 Q2 MEDICINE, GENERAL & INTERNAL
Annals of Medicine and Surgery Pub Date : 2025-05-12 eCollection Date: 2025-06-01 DOI:10.1097/MS9.0000000000003348
Manal Arshad Malik, Aleena Kamran, Dua Ahsan, Aafia Amjad, Sara Moatter, Amna Noor, Asharib Sohaib, Maryam Shaukat, Waniyah Masood, Muhammad Hasanain, Mohammed Mahmmoud Fadelallah Eljack
{"title":"Advances in management and treatment of tubercular meningitis - a narrative review.","authors":"Manal Arshad Malik, Aleena Kamran, Dua Ahsan, Aafia Amjad, Sara Moatter, Amna Noor, Asharib Sohaib, Maryam Shaukat, Waniyah Masood, Muhammad Hasanain, Mohammed Mahmmoud Fadelallah Eljack","doi":"10.1097/MS9.0000000000003348","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB), caused by <i>Mycobacterium tuberculosis</i>, continues to be a major global health issue, particularly due to its potential to cause severe complications such as tubercular meningitis (TBM), which is a fatal condition that proves difficult to diagnose and treat effectively and often results in poor outcomes, especially in children, due to delayed diagnosis, drug resistance, and limited diagnostic techniques.</p><p><strong>Methods: </strong>This review provides a comprehensive overview of recent advancements in TBM management and treatment. A systematic search was performed across major databases, including PubMed, Google Scholar, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, and the ISRCTN Registry. The search strategy used terms like (\"tubercular meningitis\" OR \"TBM\" OR \"TB meningitis\") AND (\"diagnosis\" OR \"treatment\" OR \"clinical trials\"). Inclusion criteria focused on studies published from January 2014 to September 2024, highlighting novel diagnostics, therapeutic advances, and clinical trials for TBM. Exclusion criteria involved studies unrelated to TBM or older than 10 years.</p><p><strong>Results: </strong>Diagnostic methods for TBM, such as microbiological and molecular techniques (Fig. 1), vary in sensitivity, with polymerase chain reaction assays being the most sensitive. While anti-TB drugs are available, drug resistance and poor cerebrospinal fluid penetration limit effectiveness. New molecular diagnostics and therapies, including anti-TNF agents, anti-inflammatory drugs, and antibiotics, show promise for improving outcomes.Figure 1.A summary of the diagnosis and management of tuberculosis meningitis.</p><p><strong>Conclusion: </strong>Despite recent advancements in TBM diagnostics and treatment, substantial challenges remain, particularly in addressing drug resistance and improving drug efficacy in the central nervous system. Continued innovation in molecular diagnostics and treatment approaches is essential to enhance TBM care and mitigate its devastating consequences.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"87 6","pages":"3673-3681"},"PeriodicalIF":1.6000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140737/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine and Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/MS9.0000000000003348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis, continues to be a major global health issue, particularly due to its potential to cause severe complications such as tubercular meningitis (TBM), which is a fatal condition that proves difficult to diagnose and treat effectively and often results in poor outcomes, especially in children, due to delayed diagnosis, drug resistance, and limited diagnostic techniques.

Methods: This review provides a comprehensive overview of recent advancements in TBM management and treatment. A systematic search was performed across major databases, including PubMed, Google Scholar, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, and the ISRCTN Registry. The search strategy used terms like ("tubercular meningitis" OR "TBM" OR "TB meningitis") AND ("diagnosis" OR "treatment" OR "clinical trials"). Inclusion criteria focused on studies published from January 2014 to September 2024, highlighting novel diagnostics, therapeutic advances, and clinical trials for TBM. Exclusion criteria involved studies unrelated to TBM or older than 10 years.

Results: Diagnostic methods for TBM, such as microbiological and molecular techniques (Fig. 1), vary in sensitivity, with polymerase chain reaction assays being the most sensitive. While anti-TB drugs are available, drug resistance and poor cerebrospinal fluid penetration limit effectiveness. New molecular diagnostics and therapies, including anti-TNF agents, anti-inflammatory drugs, and antibiotics, show promise for improving outcomes.Figure 1.A summary of the diagnosis and management of tuberculosis meningitis.

Conclusion: Despite recent advancements in TBM diagnostics and treatment, substantial challenges remain, particularly in addressing drug resistance and improving drug efficacy in the central nervous system. Continued innovation in molecular diagnostics and treatment approaches is essential to enhance TBM care and mitigate its devastating consequences.

结核性脑膜炎的管理和治疗进展综述。
背景:由结核分枝杆菌引起的结核病仍然是一个主要的全球健康问题,特别是因为它可能导致严重并发症,如结核性脑膜炎(TBM),结核性脑膜炎是一种致命疾病,事实证明难以有效诊断和治疗,并且由于诊断延迟、耐药性和诊断技术有限,往往导致预后不良,特别是在儿童中。方法:本文综述了TBM管理和治疗的最新进展。系统检索主要数据库,包括PubMed、谷歌Scholar、ClinicalTrials.gov、WHO国际临床试验注册平台和ISRCTN注册。搜索策略使用的术语包括(“结核性脑膜炎”或“结核性脑膜炎”或“结核性脑膜炎”)和(“诊断”或“治疗”或“临床试验”)。纳入标准侧重于2014年1月至2024年9月发表的研究,突出TBM的新诊断、治疗进展和临床试验。排除标准包括与TBM无关或年龄大于10年的研究。结果:TBM的诊断方法,如微生物和分子技术(图1),灵敏度各不相同,聚合酶链反应法是最敏感的。虽然有抗结核药物,但耐药性和脑脊液渗透性差限制了疗效。新的分子诊断和治疗,包括抗肿瘤坏死因子、抗炎药物和抗生素,显示出改善结果的希望。图1所示。结核性脑膜炎的诊断和治疗综述。结论:尽管近年来TBM的诊断和治疗取得了进展,但仍存在重大挑战,特别是在解决耐药和提高中枢神经系统药物疗效方面。分子诊断和治疗方法的持续创新对于加强TBM护理和减轻其破坏性后果至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Medicine and Surgery
Annals of Medicine and Surgery MEDICINE, GENERAL & INTERNAL-
自引率
5.90%
发文量
1665
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信